Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Equity Ratio (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Equity Ratio for 4 consecutive years, with 0.89 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 1.4% to 0.89 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.89 through Dec 2025, up 1.4% year-over-year, with the annual reading at 0.89 for FY2025, 1.4% up from the prior year.
  • Equity Ratio hit 0.89 in Q4 2025 for NewAmsterdam Pharma, down from 0.93 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.96 in Q2 2025 to a low of 0.83 in Q4 2023.
  • Historically, Equity Ratio has averaged 0.89 across 4 years, with a median of 0.88 in 2024.
  • Biggest five-year swings in Equity Ratio: decreased 8.84% in 2023 and later rose 12.67% in 2025.
  • Year by year, Equity Ratio stood at 0.91 in 2022, then decreased by 8.84% to 0.83 in 2023, then grew by 5.44% to 0.88 in 2024, then increased by 1.4% to 0.89 in 2025.
  • Business Quant data shows Equity Ratio for NAMS at 0.89 in Q4 2025, 0.93 in Q3 2025, and 0.96 in Q2 2025.